What Mazdutide is
Mazdutide is another investigational GLP-1 and glucagon receptor agonist in the obesity-drug development pipeline.
Mazdutide is grouped under Fat Loss + GLP-1s / Approved / Clinical on PeptideFactCheck because it shows up in the same conversation as other multi-agonist candidates aiming to outperform first-wave GLP-1 medicines.
The useful starting point is to separate the molecule itself from the internet story around it. It shows up in the same conversation as other multi-agonist candidates aiming to outperform first-wave GLP-1 medicines.
Why people keep looking it up
It shows up in the same conversation as other multi-agonist candidates aiming to outperform first-wave GLP-1 medicines.
Mazdutide is another investigational GLP-1 and glucagon receptor agonist in the obesity-drug development pipeline.
Mazdutide tends to stay in the conversation because it touches a familiar public theme: glp-1 receptor, glucagon receptor, and obesity research. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Early human obesity-drug evidence with no approved label in this seed set.
Human trial data exists, but it remains clinical-stage rather than approved.
Support follows multi-agonist metabolic signaling rather than settled long-term outcomes.
Why this page carries the current tier: Early human obesity-drug evidence with no approved label in this seed set.
The current seed trail for Mazdutide is pulling from 1 literature source, 1 trials source, 1 databases source, and 1 safety source.
Safety, limits, and regulatory context
As with other investigational obesity peptides, approval and safety certainty are still in progress.
Mazdutide remains investigational in the contexts tracked here.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Mazdutide. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Mazdutide is CID 167312357. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 167312357
- Formula
- C207H317N45O65
- Molecular weight
- 4476
- InChIKey
- XRBYWQZGSZWYEJ-HMQIFOERSA-N
Matched synonyms include Mazdutide, 2259884-03-0, IBI362, GTPL13924, IBI-362, GLXC-26803, compound 1 [US9938335B2], EX-A12490.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Mazdutide returns 31 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Mazdutide returns 40 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.